Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6821453 | Schizophrenia Research | 2018 | 4 Pages |
Abstract
Past studies have linked intracellular pathways related to psychotic disorders to the GSK3B enzyme. This study aimed to investigate GSK3B protein expression and phosphorylation in drug-naïve first-episode psychosis patients (n = 43) at baseline and following symptom remission, and in healthy controls (n = 77). At baseline GSK3B total level was higher in patients (p < 0.001). In schizophrenia spectrum patients (n = 25) GSK3B total and phosphorylated levels were higher than in controls and patients with other non-affective psychotic disorders (n = 18) (p < 0.001; p = 0.027; p = 0.05 respectively). No enzyme changes were found after clinical remission. The implication of this finding for the biology of psychoses warrants further studies to clarify whether increased GSK3B may be useful as a biomarker for psychosis in general, and schizophrenia in particular.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Helena P.G. Joaquim, Marcus V. Zanetti, Mauricio H. Serpa, Martinus T. Van de Bilt, Paulo C. Sallet, Tiffany M. Chaim, Geraldo F. Busatto, Wagner F. Gattaz, Leda L. Talib,